Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCED-UC: Appendectomy vs Infliximab in Left-sided Ulcerative Colitis
NCT05931458Not yet recruiting
- Sponsor
- University of Naples Federico II
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
01
Overview
Randomised, open-label trial of infliximab in ulcerative colitis (UC) (2 arms), sponsored by University of Naples Federico II. Primary endpoints: Steroid Free Clinical Remission at 12 months, Endoscopic remission at 12 months and 1 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05931458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05931458.